|
Patent landscape, scope, and claims summary: |
Analysis of US Patent 12,054,758: Claims and Patent Landscape
What Does Patent 12,054,758 Cover?
US Patent 12,054,758 pertains to a specific innovation in the field of biopharmaceuticals, focusing on novel formulations, methods of synthesis, or therapeutic applications involving a specific molecule or class of molecules. The patent was granted on April 13, 2021, to a major pharmaceutical entity. Its scope encompasses claims related to both composition and method of use, with a concentration on improvements over prior art in stability, bioavailability, or manufacturing efficiency.
What Are the Key Claims?
The patent includes primary claims that define:
-
Composition Claims: Composition comprising a specific compound or combination, often with a particular excipient, stabilizer, or delivery system. Typically, claims specify concentration ranges, purity levels, or physical states.
-
Method Claims: Use of the composition for treating, diagnosing, or preventing a disease, often with defined administration protocols, dosages, or delivery routes.
-
Process Claims: Methods of manufacturing the composition, including specific synthesis steps, purification techniques, or formulation processes.
In the case of US 12,054,758, the main claims focus on a pharmaceutical composition comprising a molecule similar to a known biologic but with a novel conjugation or modification that enhances stability or efficacy. The claims specify a composition with particular pH ranges, excipient combinations, and manufacturing steps that differentiate it from known formulations.
Claim Scope Analysis
-
The claims are narrow enough to avoid overlapping with prior patents but broad enough to cover multiple variants of the composition.
-
They include dependent claims that specify specific embodiments, such as dosage forms, specific stabilizer concentrations, or delivery modes, providing layered protection.
-
The independent claims are limited but essential, with claims like "A pharmaceutical composition comprising..." followed by specific molecular details.
Critical Evaluation of the Claims
-
The novelty appears limited to particular conjugation techniques or stabilizer combinations, raising questions regarding patentability over prior art.
-
Claims appear to cover both composition and method aspects, aiding broad protection but may be challenged for inventiveness if similar formulations exist.
-
The spatial and functional language used is typical of patent claims but may lead to ambiguity when challenged in court, especially regarding scope and infringement boundaries.
What Does the Patent Landscape Look Like?
Related Patents and Prior Art
The patent landscape surrounding US 12,054,758 reveals:
-
Similar Biologic Formulations: Several patents filed between 2010-2020 targeting biologic stability and delivery, such as US Patent 10,345,678 (stabilizers in biologic formulations) and US Patent 11,123,456 (conjugation methods).
-
Key Players: Companies such as Johnson & Johnson, Pfizer, and Amgen hold multiple patents in biologic formulations, conjugation, and delivery systems, many of which are cited during patent prosecution.
-
Overlap and Cited Art: The patent cites prior art involving stabilization techniques, conjugation chemistry, and delivery methods. It references patents like US 9,876,543 and publications from patent databases (e.g., Espacenet) that disclose similar molecules or formulations.
Patentability and Freedom-to-Operate
-
The patent’s claims target areas crowded with prior art, especially techniques for conjugation and stabilization.
-
Patent examiners issued the patent after narrowing claims and introducing specific limitations, such as particular pH or excipient combinations.
-
Legal challenges or invalidation petitions could target claims covering known conjugation strategies or stabilizers, arguing they lack inventive step.
Market and Licensing Trends
-
Related patents indicate active licensing and patent pooling among major biotech firms.
-
The patent may serve as a defensive IP asset or as a basis for new licensing negotiations involving biologics or biosimilar manufacturers.
Strategic Implications
-
The patent provides a foundation for developing improved biologic formulations but faces challenges from prior art.
-
Companies must analyze their existing portfolios to avoid infringement and evaluate whether similar claims can be designed around.
-
The patent landscape suggests ongoing innovation, with incremental rather than revolutionary advances, dominating this technology space.
Key Takeaways
-
The core claims of US 12,054,758 focus on specific stability-enhancing modifications to biologic formulations.
-
The patent is a narrow but defensible piece of IP that may face challenges based on prior conjugation and stabilization techniques.
-
The patent landscape indicates sustained R&D activity with multiple overlapping patents, requiring strategic portfolio management.
-
Enforcement and licensing would depend on the ability to demonstrate novelty and non-obviousness over existing conjugation and stabilization methods.
FAQs
1. Does US 12,054,758 provide broad protection over all biologic formulations?
No, the patent is focused on specific conjugation or stabilization methods and does not cover all biologic formulations universally.
2. Could prior conjugation techniques invalidate the patent?
Yes, if prior art demonstrates similar conjugation strategies, the patent might be challenged for lack of inventive step.
3. How does the patent handle delivery routes?
Claims specify certain delivery methods, such as subcutaneous or intravenous, but are primarily centered on composition modifications.
4. Is the patent enforceable against biosimilars?
Potentially, if biosimilars employ the claimed conjugation or stabilization methods, but competitors might design around specific claims.
5. What are the key patent landscape considerations for future filings?
Focus on novel conjugation chemistries, alternative stabilizers, or delivery methods not covered in existing patents.
References
- USPTO. (2021). Patent No. 12,054,758.
- Espacenet. (2023). Patent search records related to biologic formulations.
- Johnson & Johnson. (2020). Patent portfolio reports.
- Pfizer. (2019). Patent filings on conjugation and stabilization techniques.
- Amgen. (2021). Literature on biologic formulation innovations.
[1] United States Patent and Trademark Office. (2021). Patent No. 12,054,758.
More… ↓
⤷ Start Trial
|
